Project Grant R21EY037359
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded $173,016 to the Whitehead Institute for Biomedical Research under the Vision Research program (CFDA 93.867) for a project grant effective August 1, 2025, through July 31, 2027. This award supports systematic identification and mechanistic characterization of novel oxidative protective genes to prevent retinal pigment epithelium (RPE) degeneration in age-related macular degeneration (AMD). The research involves...
- Federal Project Grant Award Summary Massachusetts Eye and Ear Infirmary received a $663,406 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective April 1, 2026 through March 31, 2031. The award funds research to develop novel adeno-associated virus (AAV)-based therapeutics targeting retinoic acid signaling pathways to preserve cone photoreceptor function in retinitis pigmentosa (RP), an inherited retinal disease affecting approximately 1...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $435,052 Vision Research (CFDA 93.867) Project Grant to the University of Massachusetts Boston for the period July 1, 2025 through June 30, 2029. This research project will investigate the molecular and genetic mechanisms that control photoreceptor subtype specification for color vision in the fruit fly (Drosophila melanogaster) retina as a model system. The research will identify conserved transcription factors and...
- Federal Project Grant Award Summary The National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) awarded $902,000 to the University of California, San Francisco for a two-year project (September 1, 2025 – August 31, 2027) to conduct multimodal characterization of a novel inherited mouse model of glaucoma. The primary deliverables include comprehensive phenotypic characterization of GLIS1 knockout mice across two genetic backgrounds, evaluating structural and functional...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $545,948 under the Vision Research program (CFDA 93.867) to advance understanding of glaucoma pathophysiology. The award, effective April 1, 2026 through March 31, 2030, supports research investigating the role of reactive astrocytes in glaucoma progression and retinal ganglion cell (RGC) survival. The research aims to move beyond traditional neurocentric...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded $878,988 through its Vision Research program (CFDA 93.867) to The Schepens Eye Research Institute, Inc. for a five-year project (May 1, 2026 – April 30, 2031) to develop comprehensive navigation assistance technology for blind and visually impaired (BVI) individuals. The project addresses the critical "last 30 feet" problem in navigation by developing three integrated modules: AllWalk (macro-navigation with sub-foot...
- Summary of Federal Project Grant Award The University of North Carolina at Chapel Hill received a $603,053 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded April 15, 2026, with completion targeted for March 31, 2030. This award supports preclinical development of a gene augmentation therapy for IMPG2-associated retinal degeneration, a genetic condition causing juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular...
- Federal Grant Award Summary The National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), awarded University of California, Davis a $719,012 Project Grant effective August 1, 2025, through July 31, 2030, to optimize suprachoroidal adeno-associated virus (AAV) delivery systems for retinal gene therapies in nonhuman primates. The research addresses significant limitations of conventional AAV administration routes by evaluating microcatheterization techniques and...
- Federal Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded a three-year Project Grant totaling $2,674,763 to Centre Hospitalier De L'Université De Montréal (CHUM) beginning September 30, 2025, with completion targeted for September 29, 2028. This award funds research investigating interpericyte tunneling nanotubes (IPTNTs) as therapeutic targets for glaucoma treatment and vision restoration. The research will generate empirical findings...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $638,625 Project Grant to the University of California, San Diego, effective August 1, 2025 through July 31, 2028, under the Vision Research program (CFDA 93.867). The award funds research to investigate the mechanisms of drusen formation in age-related macular degeneration (AMD), a leading cause of blindness affecting approximately 196 million people globally. The research employs a novel quartz crystal microbalance assay...
The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $423,866 under the Vision Research program (CFDA 93.867) to develop mini-USH2A gene therapy for treating Usher Syndrome Type 2A (USH2A), the most common inherited condition causing combined hearing and vision loss. The research project, which commenced May 1, 2026 and concludes April 30, 2028, focuses on creating a functional minigene construct that addresses the primary challenge of delivering the large USH2A gene (15.6 kilobases) through adeno-associated virus (AAV) vectors with limited payload capacity. The institute will systematically delete repetitive domains from the USH2A protein to identify dispensable regions, then evaluate the functional efficacy of mini-USH2A variants through biochemical and cellular studies. The deliverables include characterization and functional evaluation of the identified mini-USH2A-4 construct, generation of novel mini-USH2A variants through sequential deletion of epidermal growth factor-laminin domains, and development of an AAV-based delivery approach to target the retina and cochlea in USH2A knockout mouse models. Upon successful completion, the research will establish a foundation for clinical applications to treat inherited retinal dystrophies and advance therapeutic options for USH2 patients. No sub-award information was provided for this project.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $423.9k | 4/13/26 |